dronabinol + cannabigerol

This is a **combination drug** consisting of **dronabinol** (synthetic delta-9-tetrahydrocannabinol, THC) and **cannabigerol**. Dronabinol is a synthetic cannabinoid that acts as a partial agonist at Cannabinoid-1 and Cannabinoid-2 receptors and is indicated for the treatment of anorexia associated with weight loss in AIDS patients and for nausea/vomiting associated with cancer chemotherapy[1][6][8]. Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the cannabis plant, which interacts with multiple molecular targets (including weak CB1 and CB2 receptor partial agonism, alpha-2 adrenergic receptor agonism, 5-HT1A antagonism, and various transient receptor potential channels) and is under investigation for anti-inflammatory, neuroprotective, and analgesic effects. There is no currently approved pharmaceutical product or major clinical trial for the fixed combination of dronabinol + cannabigerol, and this combination does not have a unique brand name or regulatory approval as of the present date.